Sm. Downs, HYPOXANTHINE REGULATION OF OOCYTE MATURATION IN THE MOUSE - INSIGHTS USING HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE-DEFICIENT ANIMALS, Biology of reproduction, 57(1), 1997, pp. 54-62
In this study the effects of hypoxanthine (HX) on meiotic maturation w
ere compared using oocytes from mice possessing a hypoxanthine phospho
ribosyltransferase null mutation (HPRT-) and from the corresponding HP
RT-competent background strain (HPRT+). Oocyte-cumulus cell complexes
and cumulus cell-enclosed oocytes (oocytes cultured while enclosed by
cumulus cells) from HPRT+, but not HPRT-, mice took up HX and containe
d significant levels of HPRT activity. In addition, FSH increased, and
HX suppressed, the de novo synthesis of purines in HPRT+ complexes, w
hereas de novo synthesis was elevated in HPRT- complexes and was unaff
ected by FSH or HX. After 3 h of HX treatment, lower frequencies of ge
rminal vesicle breakdown (GVB) were observed in cumulus cell-enclosed
than in denuded HPRT+ oocytes; however, identical frequencies of matur
ation were observed in denuded and cumulus cell-enclosed HPRT- oocytes
. This demonstrates a direct inhibitory action of HX on the oocyte tha
t does not depend on salvage, plus an additional action of the cumulus
cells that requires HPRT activity. Nevertheless, cumulus cells from H
PRT mice are capable of exerting an additional inhibitory action of di
butyryl cAMP (dbcAMP) on the oocyte. A kinetics analysis of FSH action
on HX-arrested cumulus cell-enclosed HPRT+ and HPRT- oocytes revealed
, first, that the inhibitory effect of the cumulus cells is transient
and, second, that HPRT activity is not required for FSH induction of G
VB in HX-arrested oocytes. When dbcAMP- or HX-arrested oocytes were tr
eated with FSH, GVB was blocked to the same extent in HPRT- oocytes wi
th the purine de novo synthesis inhibitor, azaserine, but this drug wa
s less effective in HX-treated HPRT+ oocytes. These results confirm th
e importance of the de novo pathway in hormone-induced maturation and
also support a role for purine salvage as an alternative source of nuc
leotide in this process.